<DOC>
	<DOCNO>NCT02296580</DOCNO>
	<brief_summary>This feasibility study assess effect Nativis Voyager therapy patient recurrent GBM either fail standard care intolerant therapy . The study enroll treat 64 subject 32 treated Voyager therapy alone ( monotherapy ) 32 treated Voyager plus concurrent chemotherapy . Safety clinical utility evaluate .</brief_summary>
	<brief_title>A Feasibility Study Nativis Voyager System Patients With Recurrent Glioblastoma Multiforme ( GBM )</brief_title>
	<detailed_description>This feasibility study assess effect Nativis Voyager therapy patient recurrent GBM either fail standard care intolerant therapy . The study enroll treat 64 subject 32 treated Voyager therapy alone ( monotherapy ) 32 treated Voyager plus concurrent chemotherapy . Safety clinical utility evaluate .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Subject histologically confirm diagnosis GBM . Subject fail intolerant radiotherapy . Subjects fail intolerant temozolomide therapy . Subject least one measureable lesion MRI CT. Subject least 18 year age . Subject KPS â‰¥ 60 . Subject adequate organ marrow function . Subject currently treat investigational agent . Subject receive investigational therapy within last 28 day . Subject receive surgery within last four week . Subject clinically significant electrolyte abnormality . Subject active implantable electromagnetic device . Subject metal implant , include stent , head neck incompatible MRI . Subject known HIV positive . Subject pregnant , nursing intend become pregnant course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>